BioCryst Pharmaceuticals BCRX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's financing cash flow?
- BioCryst Pharmaceuticals (BCRX) reported financing cash flow of $412.55M in Q1 2026.
- How has BioCryst Pharmaceuticals's financing cash flow changed year-over-year?
- BioCryst Pharmaceuticals's financing cash flow increased by 77887.1% year-over-year, from $529K to $412.55M.
- What is the long-term trend for BioCryst Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's financing cash flow has grown at a -0.9% compound annual growth rate (CAGR), from $359.67M to -$349.93M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.